Related news to Covid-19

Predicting Long COVID At Initial Point of COVID 19 Diagnosis - پیش بینی کووید طولانی

An ISB-led study has identified several factors that can predict if a patient is likely to develop long COVID. In this video, three of the paper’s authors – Dr. Jim Heath, Dr. Yapeng Su and Daniel Chen – discuss some of the implications of their work.

A significant portion of people who contract the SARS-CoV-2 virus – some estimates suggest more than 40 percent – suffer chronic effects known as Post Acute Sequelae of COVID-19 (PASC), commonly referred to as long COVID. PASC symptoms include fatigue, brain fog, the loss of taste and smell, shortness of breath, and more.

Now, researchers have identified several factors that can be measured at the initial point of COVID-19 diagnosis that anticipate if a patient is likely to develop long COVID. These “PASC factors” are the presence of certain autoantibodies, pre-existing Type 2 diabetes, SARS-CoV-2 RNA levels in the blood, and Epstein-Barr virus DNA levels in blood.

Additionally, researchers found that mild cases of COVID-19, not just severe cases, are associated with long COVID. They also suggest that administering antivirals very early in the disease course may potentially prevent some PASC.

“Long COVID is causing significant morbidity in survivors of COVID-19, yet the pathobiology is poorly understood,” said Dr. Jason Goldman, co-corresponding author of the paper and an infectious disease expert at Swedish. “Our study pairs clinical data and patient-reported outcomes with deep multi-omic analyses to unravel important biological associations that occur in patients with PASC. Certain findings such as the low cortisol state in patients with long COVID have potential to translate rapidly to the clinic. Our results form an important foundation for the development of therapeutics to treat long COVID.”

 

Published research paper in Cell.

Release date: 25 January 2022
Source: Institute for Systems Biology

COVID19 Vaccines Dont Cause Infertility or Harm Pregnancy Chances - تاثیر واکسن کرونا بر باروری مردان

Having a COVID-19 vaccine doesn’t impact a couple’s chances of becoming pregnant—but skipping the shots and landing a coronavirus infection might reduce male fertility.

Those are the findings in a paper published in the American Journal of Epidemiology by researchers at the Boston University School of Public Health. In a study of couples trying to conceive, they found no association between COVID-19 vaccination and the likelihood of conception in female or male partners who received the Pfizer-BioNTech, Moderna, or Johnson & Johnson vaccines.

While COVID-19 infection was not strongly associated with fertility, men who tested positive for COVID within 60 days of a given cycle had reduced fertility compared to men who never tested positive, or men who tested positive at least 60 days prior.

Release date: 20 January 2022
Source: Boston University School of Medicine

One in ten people may still be infectious for COVID after ten days - قرنطینه کرونایی

One in 10 people may have clinically relevant levels of potentially infectious SARS-CoV-2 past the 10 day quarantine period, according to new research.

The study, led by the University of Exeter and funded by Animal Free Research UK, used a newly adapted test which can detect whether the virus was potentially still active. It was applied to samples from 176 people in Exeter who had tested positive on standard PCR tests.

The study, published in the International Journal of Infectious Diseases found that 13 per cent of people still exhibited clinically-relevant levels of virus after 10 days, meaning they could potentially still be infectious. Some people retained these levels for up to 68 days. The authors believe this new test should be applied in settings where people are vulnerable, to stop the spread of COVID-19.

Professor Lorna Harries, of the University of Exeter Medical School, oversaw the study. She said: “While this is a relatively small study, our results suggest that potentially active virus may sometimes persist beyond a 10 day period, and could pose a potential risk of onward transmission. Furthermore, there was nothing clinically remarkable about these people, which means we wouldn’t be able to predict who they are”.

Conventional PCR tests work by testing for the presence of viral fragments. While they can tell if someone has recently had the virus, they cannot detect whether it is still active, and the person is infectious. The test used in the latest study however gives a positive result only when the virus is active and potentially capable of onward transmission.

Release date: 14 January 2022
Source: University of Exeter

Maternal COVID 19 Infection Increases Risks of Preterm Birth Low Birth Weight and Stillbirth - کرونای بارداری

People who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth. The poor outcomes of preterm birth and stillbirth were observed primarily with those infected with SARS-CoV-2 during the first or second trimester, whereas increased rates of small for gestational age were driven largely by third trimester infection.

An Institute for Systems Biology-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy. Researchers compared outcomes of unvaccinated people with a positive test during pregnancy – 882 in total – to those who tested negative.

The people in the study had mild or moderate SARS-CoV-2 infections. Severity of maternal COVID-19 infection was not correlated with gestational age at delivery. Additionally, poor birth outcomes were present even if maternal COVID-19 didn’t result in severe respiratory problems during infection.

The findings were published in the journal The Lancet Digital Health and are among the first that account for the trimester of SARS-CoV-2 infection on birth outcomes.

Release date: 13 January 2022
Source: Institute for Systems Biology

Vaccinated women pass COVID 19 antibodies to breastfeeding babies - انتقال ایمنی کرونایی از مادران شیرده به فرزندان

Women vaccinated against COVID-19 transfer SARS-CoV-2 antibodies to their breastfed infants, potentially giving their babies passive immunity against the coronavirus, according to University of Massachusetts Amherst research.

The study, published in the journal Obstetrics & Gynecology, measured the immune response to the COVID-19 mRNA vaccine in both breast milk and the stools of breastfed infants.

Thirty lactating women from across the U.S. – most of them healthcare workers – were enrolled in the study. They received the COVID-19 mRNA vaccine between January and April 2021. The women provided breast milk samples before they were vaccinated, across two to three weeks after their first vaccine dose and across three weeks after the second dose. They also gave samples of their blood, spotted on cards, 19 days after the first dose and 21 days after the second dose. Infant stool samples were collected 21 days after the mothers’ second vaccination. Pre-pandemic samples of breast milk, dried blood spots and infant stools were used as controls for the study.

The samples were tested for receptor-binding domain (RBD)-specific immunoglobulin (Ig)A and IgG antibodies. In the breast milk samples, anti-RBD IgG antibodies were found to neutralize the protein spike of SARS-CoV-2, as well as four variants. A significant increase in cytokine levels also revealed the immune response in breast milk samples.

Anti-RBD IgG and anti-RBD IgA antibodies were detected in 33% and 30% of infant stool samples, respectively. The levels of antibodies correlated with the vaccine side effects the mother experienced.

Release date: 07 January 2022
Source: University of Massachusetts Amherst

Booster dose of mRNA COVID 19 vaccine is required for immune protection against Omicron - واکسن کرونا و امیکرون

An additional “booster” dose of Moderna or Pfizer mRNA-based vaccine is needed to provide immunity against the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, according to a study by researchers at the Ragon Institute of MGH, MIT and Harvard. The results of this study, reported in the journal Cell, indicate that traditional dosing regimens of COVID-19 vaccines available in the United States do not produce antibodies capable of recognizing and neutralizing the Omicron variant.

In late November, health officials in South Africa reported that a previously unknown variant of SARS-CoV-2 was rapidly spreading throughout the country. The variant, given the name Omicron by the World Health Organization, would soon prove to be far more transmissible than Delta, the variant that previously had caused the majority of COVID-19 infections. “People desperately wanted to know whether current vaccines protect against Omicron,” says the senior author of the Cell paper.

To find answers, Balazs collaborated with a team that included the lead author of the Cell paper, Wilfredo F. Garcia-Beltran, MD, a clinical pathology resident at MGH and a clinician-scientist fellow at the Ragon Institute. The first step was to construct a harmless version of Omicron known as a “pseudovirus” that could be used in the laboratory to evaluate the effectiveness of the three COVID-19 vaccines available in the United States, which include the two-dose Pfizer and Moderna injections and the one-dose Johnson & Johnson vaccine. The pseudovirus that Balazs and colleagues created mimicked the behavior of Omicron, which has 34 mutations on its “spike” protein that are not found on the original strain of SARS-Cov-2 first detected in Wuhan, China, in December 2019. Scientists believe that these mutations may be partially responsible for Omicron’s rapid spread throughout the world.

Next, Garcia-Beltran worked with colleagues at MGH, including hematology-oncology fellow Vivek Naranbhai, MD, PhD, to acquire blood samples from 239 individuals who had been fully vaccinated with one of the three COVID-19 vaccines. The study subjects included employees within the Massachusetts General Brigham healthcare system and residents of Chelsea, Massachusetts, a community with a high rate of COVID-19 infections. “It was important to us to have a diverse population represented in the study,” says Garcia-Beltran. Included in this group were 70 men and women who had received a third booster dose of either the Pfizer or Moderna vaccine, according to recommendations by the Centers for Disease Control and Prevention.

Release date: 06 January 2022
Source: Massachusetts General Hospital

Babies Born During Pandemic First Year Score Slightly Lower on a Developmental Screening Test - کاهش رشد شیرخواران در زمان پاندمی

Columbia researchers found that babies born during the pandemic’s first year scored slightly lower on a developmental screening test of social and motor skills at 6 months—regardless of whether their mothers had COVID during pregnancy—compared to babies born just before the pandemic.

The study, which included 255 babies born at NewYork-Presbyterian’s Morgan Stanley Children’s Hospital and Allen Hospital between March and December 2020, was published in the journal JAMA Pediatrics.

Release date: 04 January 2022
Source: Columbia University Irving Medical Center

COVID 19 Can Trigger Self-Attacking Antibodies - کرونا و اتوآنتی بادی ها

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery—even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators. The findings are published in the Journal of Translational Medicine.

When people are infected with a virus or other pathogen, their bodies unleash proteins called antibodies that detect foreign substances and keep them from invading cells. In some cases, however, people produce autoantibodies that can attack the body’s own organs and tissues over time.

The Cedars-Sinai investigators found that people with prior infection with SARS-CoV-2, the virus that causes COVID-19, have a wide variety of autoantibodies up to six months after they have fully recovered. Prior to this study, researchers knew that severe cases of COVID-19 can stress the immune system so much that autoantibodies are produced. This study is the first to report not only the presence of elevated autoantibodies after mild or asymptomatic infection, but their persistence over time.

Some of the autoantibodies have been linked to autoimmune diseases that typically affect women more often than men. In this study, however, men had a higher number of elevated autoantibodies than women.

Release date: 03 January 2022
Source: Cedars-Sinai Medical Center

Substantial Weight Loss Can Reduce Risk of Severe COVID 19 Complications - جراحی کاهش وزن و کووید۱۹

Successful weight-loss intervention before infection associated with 60% lower risk of severe disease in patients with obesity. A Cleveland Clinic study shows that among patients with obesity, prior weight loss achieved with bariatric surgery was associated with a 60% lower risk of developing severe complications from COVID-19 infection. The research was published in the journal JAMA Surgery.

Numerous studies have established obesity as a major risk factor for developing serious illness from an infection of SARS-CoV-2, the virus that causes COVID-19. Obesity weakens the immune system, creates a chronic inflammatory state, and increases risk for cardiovascular disease, blood clots, and lung conditions. All of these conditions can complicate COVID-19.

The aim of this study was to examine whether a successful weight-loss intervention in patients with obesity prior to contracting COVID-19 could reduce the risk of developing a severe form of this disease.

A total of 20,212 adult patients with obesity were included in this observational study. A group of 5,053 patients with a body mass index (BMI) of 35 or greater who had weight-loss surgery between 2004 and 2017 were carefully matched 1:3 to non-surgical patients, resulting in 15,159 control patients. Compared with those in the non-surgical group, patients who had bariatric surgery lost 19% more body weight prior to March 1, 2020 (the beginning of the COVID-19 outbreak in Cleveland).

After the COVID-19 outbreak, researchers looked at four COVID-19-related outcomes: rate of contracting SARS-CoV-2 infection, hospitalization, need for supplemental oxygen and severe disease (defined as a combination of ICU admission, need for mechanical ventilation or death).

Although the rate of contracting SARS-CoV-2 was similar between the groups (9.1% in the surgical group and 8.7% in the non-surgical group), participants in the weight-loss surgery group experienced much better outcomes after contracting COVID-19 compared with those in the non-surgical group. Researchers found that patients with prior weight loss surgery had a 49% lower risk of hospitalization, 63% lower risk of need for supplemental oxygen, and 60% lower risk of developing severe COVID-19.

Although the exact underlying mechanisms are not known, these data suggest that patients who underwent weight-loss surgery were healthier at the time of contracting a SARS-CoV-2 infection, which resulted in better clinical outcomes.

Release date: 16 December 2021
Source: Cleveland Clinic

The Best Time for COVID 19 Vaccination During Your Pregnancy - زمان مناسب واکسیناسیون کرونا در مادران باردار

COVID-19 vaccination of expectant mothers elicits levels of antibodies to the SARS-CoV-2 outer “spike” protein at the time of delivery that don’t vary dramatically with the timing of vaccination during pregnancy and thus don’t justify delaying vaccination, according to a study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

The researchers, whose study was published in Obstetrics & Gynecology, analyzed how anti-spike antibody levels in the mother’s blood and baby’s umbilical cord blood at delivery varied with the timing of prior vaccination in nearly 1,400 women and their babies.

They found that the levels of these antibodies at delivery tended to be higher when the initial vaccination course occurred in the third trimester. However, they also found that antibody levels at delivery are still comparably high, and probably still protective, when vaccination occurs in early pregnancy or even a few weeks before pregnancy—and a booster shot late in pregnancy can make those antibody levels much higher.

“Women often ask what is the best vaccination timing for the baby—our data suggest that it’s now,” said Dr. Malavika Prabhu, assistant professor of obstetrics and gynecology at Weill Cornell Medicine and an obstetrician and gynecologist at NewYork-Presbyterian/Weill Cornell Medical Center.

Release date: 28 December 2021
Source: Weill Cornell Medicine